Physician profile
Preetham Reddy
NPI 1720059280
$27,989.49
in general payments reported to CMS, 2019-2025
14 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $35.81 · 2021: $198 · 2022: $33.65 · 2023: $14.73 · 2024: $140 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $27K · Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $27,225.57 |
| Food and Beverage | $304.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27,256.67 | 2023-2025 | General - Therapies, Eluvia |
| Astrazeneca Pharmaceuticals LP | $154.02 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $134.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.49 | 2024-2025 | |
| Ardelyx, INC. | $78.87 | 2024-2025 | Ibsrela |
| Amgen INC. | $67.82 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $49.88 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $39.61 | 2022-2025 | |
| Inari Medical, INC. | $35.46 | 2019-2020 | |
| Travere Therapeutics, INC. | $32.27 | 2022-2025 | |
| Pfizer INC. | $14.67 | 2024 | |
| Daiichi Sankyo INC. | $14.65 | 2025 | Injectafer |
| Nxstage Medical, INC. | $13.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preetham Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.